# An Open-label, Dose Escalation Study to Assess the Pharmacokinetics of of ASA404 in Adult Cancer Patients With Impaired Hepatic Function

> **NCT01278849** · PHASE1 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 5 (actual)

## Conditions studied

- Histologically-proven and Radiologically-confirmed Solid Tumors

## Interventions

- **DRUG:** ASA404

## Key facts

- **NCT ID:** NCT01278849
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-01
- **Primary completion:** 2010-11
- **Final completion:** —
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2020-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01278849

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01278849, "An Open-label, Dose Escalation Study to Assess the Pharmacokinetics of of ASA404 in Adult Cancer Patients With Impaired Hepatic Function". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01278849. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*